Off Patent
December 2027

Incruse Ellipta

umeclidinium bromide

Glaxo Group Ltd England dba Glaxosmithkline

Powder (inhalation) · NDA 205382

Last listed protection ends
December 18, 2027

The FDA lists 1 patent for Incruse Ellipta, and this is the day the last one ends. It is not the date a generic goes on sale.

Patents and exclusivities

  1. Patent 7,488,827
    Claims the drug substance and the drug product